Glimepiride 1 - 2mg + Metformin HCl 500mg
  • Mode of action

    Glimepiride stimulates the insulin release from functioning pancreatic β-cells and inhibits gluconeogenesis at hepatic cells. It also increases insulin sensitivity at peripheral target sites. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).

  • Indication

    For the management of patients with type 2 diabetes mellitus when diet, exercise and single agent (glimepiride or metformin alone) do not result in adequate glycemic control

  • Side effects

    Diarrhoea, vomiting, metallic taste, rash, isolated transaminase elevations, cholestatic jaundice, allergic skin reactions, photosensitivity reactions, leukopaenia, agranulocytosis, thrombocytopaenia, haemolytic anaemia, aplastic anaemia, pancytopaenia, blurred vision. Special Precautions Renal and hepatic impairment. Avoid alcohol consumption. Hypoglycaemic episodes.

  • Dose


    Type 2 diabetes mellitus

    Adult: Per tablet contains glimepiride 1 mg and metformin 250 mg or glimepiride 2 mg and metformin 500 mg: Take as directed. Titrate according to response.